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ABSTRACT
Herbal formulations marketed in India for many years providing its therapeutic benefits in health problems. Medicinal plants or their phytoconstituents 
are less toxic and free from side effects than synthetic drugs. However, formulation aspects of these phytoconstituents are limited due to its low 
solubility. Nanotechnology is a promising technique to increase the solubility of herbal drugs. This will lead to a subsequent reduction in drug dose. 
Nanoformulations such as nanosuspension increase the solubility of poorly soluble drugs and also have good targeting effects on different cells. The 
efficacy of herbal nanosuspensions evaluated using different cell lines. Here, hepatocellular carcinoma cell line (SMMC-7721), human prostate cancer 
cell line, human myelogenous leukemia cell line, human epithelial cell line, human breast cancer cell lines (4T1, MCF-7, and MDA-MB-453), carcinomic 
human alveolar basal epithelial cell line (A549), human umbilical vein endothelial cell line, human colorectal adenocarcinoma cell line (HT-29), and 
human epithelial carcinoma cell line (HeLa) are used in the evaluation procedures. In vitro assays help in the determination of the dose range of drugs 
for the activity. The present review highlights the in vitro cancer studies of herbal nanosuspensions using different cell lines.
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INTRODUCTION
Herbal medicines are used all over the world due to their low toxicity 
and reduced side effects than synthetic drugs [1]. The greater part 
of the active constituents of herbal extract is ineffective to pass 
lipid membranes due to their high molecular size or low solubility. 
Nanosuspension technology is introduced as a result of many efforts 
made by formulation scientists and emerged as a potent candidate for 
the delivery of the poorly soluble drugs in a more efficient manner. 
Hence, herbal extract in the form of nanosuspension may be beneficial 
for the treatment of various diseases [2].
In vitro bioassays are important in the evaluation of these herbal 
nanosuspensions with possible pharmacological effects [3]. Cell-based 
bioassays are used to find the pharmacological activity of formulations, 
and for this purpose, it requires identification of a responsive cell 
line. A cell line can proliferate indefinitely in an appropriate fresh 
medium and space. These have a major role in studying physiological, 
pathophysiological, and differentiation process of exact cells [4]. The 
cell lines possess many characteristics of normal cells, so these are 
used in the studies to determine whether medicinal plants have defined 
pharmacological activities [5].
TYPES OF CELL LINES
Finite cell lines
The cell in culture divides only a limited number of times before 
their growth rate decreases, and finally, they will die. The cell lines 
with limited culture life spans are known as finite cell lines. The cells 
normally divide 20–100 times before destruction. The human cells 
divide 50–100 times.
Continuous cell lines
A few cells in culture may get different morphology and get modified. 
Such types of cells are capable of growing faster and resulting in an 
independent culture. The progeny obtained from these modified cells 
have an unlimited life. They are known as continuous cell lines. These 
are transformed, immortal, and tumorigenic.
SELECTION OF CELL LINE
Species
Species differences are important while extrapolating the data to 
humans.
Finite or continues cell lines
Cultures with continuous cell lines are preferred due to their high yield.
Normal or transformed cells
The transformed cells are preferred because they are immortalized and 
grow quickly.
Availability
It may be produced in the laboratory.
Stability
The stability of a cell line related to cloning and storage.
Growth characteristics
•	 Population doubling time
•	 Ability to grow in suspension
•	 Saturation density
•	 Cloning efficiency [6].
IN VITRO CANCER CELL LINE STUDY
In vitro evaluation of curcumin nanosuspension against HeLa cell 
lines
Curcumin is the active ingredient present in the plant turmeric ( 
Curcuma longa ) [7], and it has a wide range of pharmacological activities 
including anti-cancer, anticoagulant, antithrombotics, antioxidation, 
and antiproliferation[8]. Curcumin used to treat the regression of 
psoriasis, pre-malignant lesions of the bladder, also the treatment of 
many cancers such as the cervix, soft palate, stomach, colorectal, and 
skin cancers [9-13]. Curcumin can be considered as a prospective drug 
due to its high safety and low cost [14].
HeLa cell lines are the most commonly used human immortal cell 
lines [15]; originally, it was reported from a female African-American 
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individual in 1952 as cervical epithelial carcinoma, consequent analysis 
of tumor pathology, and clinical phenotype identified the first tumor as 
an uncommon adenocarcinoma [16]. HeLa has a powerful adaptation to 
culture conditions because it was the first cell line widely cultured [17]. 
It is epithelial in appearance grows fast with a doubling time of 24 h and 
shows a scarcity of contact inhibition [18]. These cells can proliferate 
rapidly compared to other cancer cells [19]. The stable growth of HeLa 
enabled the development of the polio vaccine [20], and also it is used by 
scientists in different types of investigations such as disease research, 
gene mapping, effects of toxic substances in organisms, and radiation 
on humans [21].
The anticancer activity of curcumin nanosuspension was assessed 
by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) method. The HeLa cells were exposed to curcumin 
nanosuspension and free curcumin solution at different concentrations 
(5, 10, 20, 40, 80, 160 µg/ml) for 3 days. Empty excipients as negative 
control were added at equivalent concentrations as that within the 
tested curcumin nanosuspension. The curcumin nanosuspension 
and free curcumin solution inhibited the growth rate of tumor cells 
in a dose-dependent manner. This study suggested that curcumin 
nanosuspension shows higher anticancer activity than free curcumin at 
the same concentration due to the presence of nano-sized particles [22].
In vitro evaluation of silybin nanosuspension against prostate 
cancer cell lines (PC-3) and human epithelial cell line (Caco-2) cell 
lines
Silybin is a chemical constituent isolated from milk thistle plant 
(Silybum marianum) and used as a therapeutic agent for a variety of 
diseases, including human colon cancer, liver disease, and prostate 
cancer. It also suppresses the cell growth and DNA synthesis, and it 
is chemopreventive targeting inhibit the invasive process in prostate 
cancer [23-25]. This herb can be used in beta-thalassemia patients 
due to its immunomodulatory, iron-chelating, and antioxidant 
properties [26,27].
PC3 cell lines are human prostatic adenocarcinoma cell line that is used 
in prostatic adenocarcinoma research and drug development. These 
were isolated from bone metastasis and grew as an adherent layer [28]. 
It helps to determine biochemical changes in advanced prostate cancer 
cells and assessing their response to chemotherapeutic agents [29]. 
Other PCs-3 such as DU145 and LNCaP have low metastatic potential 
compared to PC-3 cell lines [30]. Protein expression of PC-3 cells may 
be a characteristic of small cell neuroendocrine carcinoma [31]. For 
the generation of subcutaneous tumor xenografts in mice, these cell 
lines can act as a good tool. Hence, it helps to investigate the tumor 
environment and therapeutic drug functionality [32].
Antitumor effect of prepared silybin nanosuspension and free silybin 
was done against the PC-3 cell line in an in vitro model and evaluated 
at different concentrations (0.2, 1, 2, 10, 20, and 100 µg/ml ) for 12, 
24, 3, and 48 h by MTT reduction assay. The inhibition rate of silybin 
nanosuspension to PC-3 cells increased with the concentration and 
time. This study suggested that silybin nanosuspension shows a higher 
inhibition rate than free silybin at the same concentration [33].
Caco-2 cell line originates from the human colon adenocarcinoma 
tissue, and it forms a monolayer of polarized enterocytes through 
spontaneous cellular differentiation. Caco-2 cells are shown to explicit 
many enzymes and display all of the four different transport routes of 
the intestinal epithelium [34]. Furthermore, the Caco-2 monolayer is a 
good in vitro model of human small intestine mucosa[35].
The anticancer activity of silybin nanosuspension against the Caco-2 
cell line was determined by MTT assay. It was performed to measure 
the cellular viability. For the study, cell lines were incubated with silybin 
formulations for 8 h and 48 h at a concentration range of 10–500 µg/ml−1. 
When the concentration of silybin was below 125 µg/ml−1, there was no 
significant difference between the experimental group and the control 
group. Hence, this study was stated that nanosuspensions were related 
to no cytotoxic below the concentration of 125 µg/ml−1 [36].
In vitro evaluation of oridonin nanosuspension against human 
myelogenous leukemia cell line (K562) and SMMC-7721 cell lines
Oridonin is a natural ent-kaurane diterpenoid extracted from the 
various plants such as Isodon trichocarpus, Isodon japonicas, and 
Isodan shikokianus [37-39]. It has various pharmacological effects 
including anti-inflammation, anti-bacterial, and anti-tumor activity. 
Mainly, it used to treat human cancers, including prostate cancer, breast 
cancer, and lung cancer [40-42].
K562 cell lines are myelogenous leukemia cell lines that produce less 
clumping in culture due to the downregulation of surface adhesion 
molecules by the fusion gene [43]. The cells are non-adherent and 
round; also, it shows a proteomic resemblance to undifferentiated 
granulocytes [44] and erythrocytes [45]. They easily destroyed by 
natural killer cells [46] because they lack the major histocompatibility 
complex required to inhibit natural killer cell activity [47].
The in-vitro anticancer activity of oridonin nanosuspension against 
K562 cell was determined by MTT assay at different concentrations 
of oridonin nanosuspension and free oridonin solution (5, 10, 20, 
30, and 40 µmol/l). The incubation time was 12, 18, 24, and 36 h. 
The anticancer activity of oridonin nanosuspension increases with 
the concentration and incubation time. This study suggested that the 
oridonin nanosuspension shows more anticancer activity than a free 
oridonin solution at the same concentration. Moreover, this enhanced 
effect due to the presence of nanoparticles [48].
The SMMC-7721 cell line was derived in 1977 from hepatocellular 
carcinoma patients. This cell line expresses two receptors, that is, 
epidermal growth factor receptor and vascular endothelial growth 
factor receptor. It is an useful tool in liver cancer research [49].
MTT assay was used to determine the in vitro anticancer activity of 
the oridonin nanosuspension compared to the free oridonin solution 
against the SMMC-7721 cell line. The different concentrations 
(5, 10, 20, 30, and 40 µmol/l) of oridonin nanosuspension and the free 
oridonin solution used for the cell line study. The incubation period 
was 12, 24, 36, and 48 h. Both nanosuspension and free solution 
inhibited the growth of SMMC-7721 cells in a time-dose-dependent 
manner. This study suggested that at the same concentration, oridonin 
nanosuspension showed a higher inhibition rate against SMMC-7721 
cell line than a free oridonin solution. It may be due to the presence of 
a high concentration of free oridonin or uptake of nanoparticles or the 
combination of both [50].
In vitro evaluation of gambogenic acid nanosuspension against 
hepatocellular carcinoma cell line (HepG2) cell line
Gamboge is a herbal medicine derived from Garcinia hanburyi tree, 
and it shows pharmacological activities such as detoxification, anti-
inflammatory, and parasiticide effects. The main active constituent 
present in the plant includes gambogenic acid and gamboge. 
Gambogenic acid has a broad-spectrum anti-tumor effect in different 
cancer cell lines [51,52].
HepG2 is a human liver cancer cell line isolated from the liver tissues. 
This immortal cell line used in drug metabolism and hepatotoxicity 
studies [53,54]. These cells are epithelial in morphology, and various 
proteins such as albumin, fibrinogen, transferrin, and plasminogen 
are secreted from these HepG2 cell lines [55]. At suitable culture 
conditions, HepG2 cell lines show robust morphological and functional 
differentiation [56]. These are good in vitro model system for the study 
of intracellular trafficking, dynamics of bile canalicular, sinusoidal 
membrane proteins, and lipids in human hepatocytes [57].
The anti-tumor activity of gambogenic acid nanosuspension on the 
HepG2 cell line was determined by MTT assay. The HepG2 cell line 
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was exposed to different concentrations (0.5, 1, 2, 4, 8, and 16 µM) of 
gambogenic acid nanosuspension and free gambogenic acid solution for 
48 h. The cytotoxicity of the gambogenic acid solution and gambogenic 
acid nanosuspension depends on the dose and concentration rate. 
This study suggested that the gambogenic acid nanosuspension has 
significant cytotoxicity to HepG2 cells than a gambogenic acid solution 
at an equivalent dose and it may be due to uptake of nanoparticles [58].
In vitro evaluation of Genkwanin nanosuspension against 4T1, 
MCF-7, MDA-MB-453, A549, and human umbilical vein endothelial 
cell line (HUVEC) cell lines
Genkwanin is a flavonoid isolated from Genkwa flos, Rosmarius 
officinalis [59], and the leaves of Cistus laurifolius [60]. It is known 
as a representative marker for quality control of traditional Chinese 
prescriptions [61]. It has various pharmacological effects, including 
antitussive, expectorant, anti-inflammatory [62], anti-bacterial [63], 
anti-plasmodial [64], radical scavenging [65], chemoprotective [66], 
and inhibiting 17β-hydroxysteroid dehydrogenase type 1 activities [67].
4T1 is a breast cancer cell line isolated from the mammary gland tissue 
of the mouse. These epithelial cells are resistant to 6-thioguanine [68]. 
It is mainly used to study breast cancer metastasis [69], and in live 
tissues, it is highly aggressive [70].
The MCF-7 is a breast cancer cell line isolated from Caucasian 
women [71,72] and acronym of Michigan cancer foundation-7 [73]. This 
noninvasive cell line represents a model of early-stage disease [74].
MDA-MB-453 cell line is a human breast cancer cell line and it has an 
active glycerol3-phosphate shuttle [75].
A549 cells are human epithelial cell lines developed in 1972 [76]. 
These types of cell lines are human alveolar basal epithelial cells [77]. 
These cell lines used for the study of lung cancer and also used for 
developing a drug against lung cancer [78,79]. It is responsible for the 
diffusion of water and electrolytes across alveoli. It is widely used as a 
type 2 pulmonary epithelial cell model for drug metabolism [80]. It is 
employed in viral research and also been studied for cell line response 
to tuberculosis [81,82].
HUVEC cell lines are derived from human umbilical vein endothelial 
cells in the 1970s and used as a laboratory model system for the study 
of the function and pathology of endothelial cells [83,84].
Anticancer activity of Genkwanin nanosuspension and Genkwanin 
solution against 4T1, MCF-7, MDA-MB-453, A459, and HUVEC cell lines 
assessed using MTT assay. Various concentrations (0.5, 1, 2, 5, 10, 20, 
50, 100 µg/ml) of Genkwanin nanosuspension and Genkwanin solution 
were used for the study. The incubation time was 48 h. Both Genkwanin 
nanosuspension and Genkwanin solution inhibited cell proliferation 
in a dose-dependent way. This study suggested that Genkwanin 
nanosuspension exhibited higher cytotoxicity than the Genkwanin 
solution against all studied cell lines [85].
In vitro evaluation of puerarin nanosuspension against HT-29 cell 
line
Puerarin is an isoflavone [86] isolated from the root of the 
Pueraria lobata [87]. It have many beneficial effects on liver 
disease [88,89],cardiovascular [90,91], neurological [92,93], anti-
platelet aggregation [94], and hyperglycemic disorders [95]. 
Furthermore, it exhibits protective actions against fever, inflammation, 
hyperlipidemia, osteonecrosis, and oxidative damage [96].
HT-29 cell lines are a colon cancer cell line utilized in cancer 
research [97]. These cells are useful for somatic cell research due to 
their ability to differentiate and simulate real colon tissue in vitro [98]. 
HT-29 cells can proliferate in cell culture with a doubling time of 
around 4 days without using the growth factors. The doubling time is 
often reduced to 1 day with added fetal bovine serum [99]. The HT-
29 cells have shown induced differentiation [100], with galactose-
mediated differentiation, also results in the strengthening of adherens 
junctions [101].
The antitumor activity of puerarin nanosuspension was evaluated by 
MTT assay. Various concentrations (1.25, 2.5, 12.5, and 25 µg/ml−1) of 
puerarin nanosuspension and puerarin solution incubated for 8, 16, 
and 24 h. Both the puerarin nanosuspension and puerarin solution 
inhibited the cell proliferation of HT-29 in a concentration time-
dependent manner. This study suggested that compared with puerarin 
free solution, nanosuspension of puerarin showed a significant increase 
in the cell inhibition rates under the same concentrations. The inhibitory 
effects increased with concentration and incubation time [102].
CONCLUSION
Herbal drugs have low side effects than synthetic drugs and also if it is 
formulated as nanosuspensions that it increases the solubility of drugs 
than conventional dosage forms. For the in vitro evaluation of herbal 
nanosuspensions, cell lines are mostly preferred. Because it offers easy, 
inexpensive, and stable platforms for the study. Here, HepG2, PC-3, 
K562, Caco-2, SMMC-7721,4T1, MCF-7, MDA-MB-453, A549, HUVEC, 
HT-29, and HeLa cell lines are used in the evaluation of different herbal 
nanosuspensions. Each cell line is derived from various organs and 
sources. MTT assays are the most commonly used method in the cell 
line studies to estimate the number of viable cells in multi-well plates. 
Cell metabolic activity can be determined using this assay method. 
Hence, cell lines can be used as an in vitro model for evaluation of herbal 
nanosuspensions.
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